Journal article
Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
Alzheimer's & dementia, Vol.18(10), pp.1969-1979
10/2022
DOI: 10.1002/alz.12620
PMCID: PMC9402800
PMID: 35213786
Abstract
Alzheimer's disease (AD) begins with an asymptomatic "preclinical" phase, in which abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed in research settings, and is moving toward clinical settings with the development of cheaper and non-invasive testing. Limited research has focused on the safety and psychological effects of disclosing biomarker results to cognitively unimpaired adults. However, less is known about how to ensure equitable access and robust counseling for decision-making before testing, and how to effectively provide long-term follow-up and risk management after testing. Using the framework of Huntington's disease, which is based on extensive experience with disclosing and managing risk for a progressive neurodegenerative condition, this article proposes a conceptual model of pre-disclosure, disclosure, and post-disclosure phases for AD biomarker testing. Addressing research questions in each phase will facilitate the transition of biomarker testing into clinical practice.
Details
- Title: Subtitle
- Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
- Creators
- Fred B Ketchum - University of Wisconsin–MadisonNathaniel A Chin - University of Wisconsin–MadisonJoshua Grill - University of California, IrvineCarey E Gleason - University of Wisconsin–MadisonClaire Erickson - University of Wisconsin–MadisonLindsay R Clark - University of Wisconsin–MadisonJane S Paulsen - University of Wisconsin–MadisonAmy J H Kind - University of Wisconsin School of Medicine and Public Health
- Resource Type
- Journal article
- Publication Details
- Alzheimer's & dementia, Vol.18(10), pp.1969-1979
- DOI
- 10.1002/alz.12620
- PMID
- 35213786
- PMCID
- PMC9402800
- NLM abbreviation
- Alzheimers Dement
- ISSN
- 1552-5260
- eISSN
- 1552-5279
- Grant note
- P30 AG062715 / NIH HHS R03 AG062975 / NIA NIH HHS R01 AG054059 / NIA NIH HHS RF1 AG057547 / NIH HHS P30 AG066519 / NIH HHS RF1 AG057784 / NIA NIH HHS UL1 TR001414 / NCATS NIH HHS R01 AG062307 / NIA NIH HHS NIA U24 AG057437 / NIH HHS R03 AG062975 / NIH HHS R01 AG054059 / NIH HHS P30 AG066519 / NIA NIH HHS U24 AG057437 / NIA NIH HHS RF1 AG057547 / NIA NIH HHS RF1 AG057784 / NIH HHS NCATS UL1 TR001414 / NIH HHS R01 AG070883 / NIA NIH HHS P30 AG062715 / NIA NIH HHS R01 AG070883 / NIH HHS R01AG062307 / NIH HHS
- Language
- English
- Date published
- 10/2022
- Academic Unit
- Psychiatry; Psychological and Brain Sciences
- Record Identifier
- 9984383284002771
Metrics
26 Record Views